 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)
|
|
|
|
Phase IV
|
|
|
|
G-PCNSL-SG1
NCT00153530
|
|
| |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
|
|
|
|
Phase III, Phase II
|
|
|
|
RPCI-I-72806
I 72806, NCT00536601
|
|
| |
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
|
|
|
|
Phase III
|
|
|
|
DSHNHL 2006-1B / ACT-2
BMBF GFVT 01014715, NCT00725231
|
|
| |
Tetrodotoxin Open-Label Efficacy and Safety Continuation Study
|
|
|
|
Phase III
|
|
|
|
TEC-006OL
NCT00726011
|
|
| |
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
|
|
|
|
Phase II, Phase I
|
|
|
|
RTOG-0227
RTOG-0227, NCT00068250
|
|
| |
Rituximab, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
|
|
|
|
Phase II, Phase I
|
|
|
|
OHSU-1012
OHSU-SOL-05025-L, NCT00293475
|
|
| |
Allogeneic Cytokine-Induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies
|
|
|
|
Phase II, Phase I
|
|
|
|
CIK#2/2007
NMRC/1097/2006, NCT00460694
|
|
| |
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With T-Cell Diseases
|
|
|
|
Phase II, Phase I
|
|
|
|
FDA IND 100712
96-MH-01, NCT00611208
|
|
| |
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
|
|
|
|
Phase II, Phase I
|
|
|
|
CLBH589B2102
NCT00621244
|
|
| |
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
|
|
|
|
Phase II, Phase I
|
|
|
|
25223
PSU25223, NCT00626626
|
|
